Handelsavisen
prelaunch
Companies Healthcare MLSS.K
ML
MLSS.K NYSE Advanced Medical Equipment & Technology

Milestone Scientific Inc

$0,33
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
28,9M USD
P/E
EV / Rev
Div yield
Op margin
-63,5 %
ROE
-203,4 %
Net margin
-63,8 %
Debt / equity
0,30
Beta
52w range
Volume
237
Day range
$0,39–$0,40
Prev close
$0,39
Open
$0,39
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Milestone Scientific Inc develops and markets computer-controlled drug delivery systems for use in dental and medical applications, generating revenue primarily through the sale of its proprietary devices and related consumables.

Business. Milestone Scientific Inc (MLSS.K) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NYSE under the ticker symbol MLSS.K.

Classification99 %
SectorHealth Care
Industry groupAdvanced Medical Equipment & Technology
Generated · model-assisted
Sell-side consensus
BUY2 analysts
2 buy0 hold0 sell
Avg 12m price target1,00

Analyst recommendations

2 analysts · consensus Buy
Buy2
Hold0
Sell0
12-month price target
1,00
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
2 analysts · indicative
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-203,4 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning MLSS.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to MLSS.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Milestone Scientific Inc (MLSS.K) is a healthcare services and equipment company specializing in advanced medical equipment and technology. The firm operates within the Advanced Medical Equipment & Technology industry, focusing on product sales. Headquarters and specific operating segment details are not provided in the available data. The company is listed on the NYSE under the ticker symbol MLSS.K.

    Classification99 %
    SectorHealth Care
    Industry groupAdvanced Medical Equipment & Technology
    AI synthesis
    GENERATED

    Milestone Scientific Inc operates with a market capitalization of $27.41 million and a price-to-book ratio of 9.75, indicating a premium valuation relative to its book value. The company's liquidity position is characterized by $1.11 million in cash and equivalents, but it is offset by negative operating and free cash flows of -$2.92 million and -$5.66 million, respectively, signaling potential short-term liquidity constraints. The current ratio of 1.81 suggests the company can cover its current liabilities with its current assets, but the negative operating cash flow raises concerns about its ability to sustain operations without external financing.

    Profitability metrics reveal a challenging financial landscape for Milestone Scientific Inc. The company reported a net loss of $5.72 million and an operating loss of $5.70 million, resulting in a return on equity of -2.03% and a return on assets of -0.73%, both significantly below industry norms. These figures indicate that the company is not generating returns for its shareholders or effectively utilizing its assets to generate profit.

    Geographically, Milestone Scientific Inc's revenue is not disclosed by region, but its business model is heavily reliant on the sale of proprietary devices and consumables, which may expose it to market concentration risks in the dental and medical sectors. The company's exposure to these segments is not diversified, and any downturn in demand for its products could have a material impact on its financial performance.

    Looking ahead, the company's growth trajectory is uncertain. Analysts have provided a mean price target of $1.00, which is significantly higher than the current market price of $0.31, but the lack of strong buy recommendations and the presence of only two buy ratings suggest limited confidence in the company's near-term prospects. The company's revenue history does not provide a clear indication of growth, and the absence of positive operating cash flow further complicates its ability to invest in future growth initiatives.

    Risk factors for Milestone Scientific Inc include its negative net income and operating income, which could lead to increased financial leverage or the need for additional financing. The company's debt-to-equity ratio of 0.3 is relatively low, but the negative cash flows and operating losses could increase this ratio if the company needs to take on more debt to fund operations. The risk assessment indicates low liquidity and dilution risks, but the negative cash flows and operating losses could change this if the company needs to issue more shares to raise capital.

    Recent events and filings do not indicate any immediate liquidity or dilution flags, but the company's financial performance suggests that it may need to seek additional financing in the near term. The absence of positive cash flows and the presence of negative operating and free cash flows highlight the need for the company to address its financial challenges to maintain its operations and growth prospects.

    Key takeaways
    • Milestone Scientific Inc is trading at a price-to-book ratio of 9.75, indicating a premium valuation despite negative earnings.
    • The company reported a net loss of $5.72 million and an operating loss of $5.70 million, with a return on equity of -2.03% and a return on assets of -0.73%.
    • Milestone Scientific Inc has $1.11 million in cash and equivalents but is generating negative operating and free cash flows, raising concerns about its liquidity.
    • Analysts have provided a mean price target of $1.00, but the lack of strong buy recommendations suggests limited confidence in the company's near-term prospects.
    • The company's debt-to-equity ratio is 0.3, but the negative cash flows and operating losses could increase this ratio if the company needs to take on more debt to fund operations.

    Bull / Bear case

    Generated · model-assisted
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $0,33
    Market cap
    $27.4M
    Enterprise value
    $27.2M
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    9.8x
    P / Tangible book
    9.8x
    Tangible book
    $2.8M
    Net cash
    $257.9k
    Current ratio
    1.8
    Debt / equity
    0.3
    ROA
    -73.3%
    ROE
    -2.0%
    Cash conversion
    51.0%
    CapEx / revenue
    -0.2%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    INDUSTRYSEGMENTCOMPANYHealthcareIndustryAdvanced Medical Equipment & Technology170,9B node revenueTMO 26,1%DHR 14,4%GEHC 12,1%PHG 11,9%BSX 11,7%ISRG 5,9%A 4,1%EW 3,5%Other 10,4%
    Source: company disclosures · own-taxonomy revenue-covered setMLSS 0,0% · rank #36 of 46

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs MLSS · multiples and returns
    TM
    TMO
    Thermo Fisher Scientific Inc
    $574,03
    214,1B USD
    P/E
    29,4x
    vs self
    Div yield
    0,3 %
    vs self
    ROE
    12,9 %
    +216,4 vs self
    DH
    DHR
    Danaher Corp
    $197,50
    140,1B USD
    P/E
    38,2x
    vs self
    Div yield
    vs self
    ROE
    6,9 %
    +210,3 vs self
    GE
    GEHC
    GE HEALTHCARE TECHNOLOGIES INC.
    $69,72
    31,9B USD
    P/E
    13,6x
    vs self
    Div yield
    0,2 %
    vs self
    ROE
    19,5 %
    +223,0 vs self
    PH
    PHG
    PHG
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    BS
    BSX
    Boston Scientific Corp
    $48,54
    72,6B USD
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    IS
    ISRG
    INTUITIVE SURGICAL, INC.
    $376,00
    133,2B USD
    P/E
    287,7x
    vs self
    Div yield
    vs self
    ROE
    3,6 %
    +207,0 vs self
    A
    A
    Agilent Technologies Inc
    $139,80
    39,6B USD
    P/E
    29,0x
    vs self
    Div yield
    0,8 %
    vs self
    ROE
    19,3 %
    +222,8 vs self
    EW
    EW
    Edwards Lifesciences Corp
    $88,82
    51,6B USD
    P/E
    44,3x
    vs self
    Div yield
    vs self
    ROE
    10,4 %
    +213,8 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    -0,04
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    2
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-03 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate-0,04
    Revenueno estimateno estimate9,9M USD
    Operating incomeno estimateno estimate-3,7M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution2 analysts
    Strong buy0
    Buy2
    Hold0
    Sell0
    Strong sell0
    12-month price target$1,00 · Median $1,00
    Low $1,00High $1,00
    Operating income · consensus-3,7M USD
    EPS surprise
    −55,6 %
    reported vs consensus · miss
    Revenue surprise
    −9,4 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$1,00
    Mean$1,00
    Median$1,00
    High$1,00
    Spot$0,33
    +206.1 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-63,5 %Below median
    Net Margin-63,8 %Below median
    ROE-203,4 %Bottom quartile
    Capex / Rev-0,2 %Above P75
    D/E0,30Below median
    Cash Conv0,51Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Milestone Scientific Inc Market data — financials · 2026-05-28
    • Milestone Scientific Inc Market data — analyst estimates · 2026-05-28

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$1M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • State Street Investment Management (US)Investment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M

    Insider activity

    Net selling0 buys · 13 sellsnet -$174K1 insiders · last 365d
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 100 000 @ $0,44$44K · 2025-10-24
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 80 000 @ $0,43$34K · 2025-10-23
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 14 427 @ $0,45$6K · 2025-10-22
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 40 000 @ $0,44$18K · 2025-10-21
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 24 034 @ $0,45$11K · 2025-10-20
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 30 000 @ $0,54$16K · 2025-10-14
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,55$6K · 2025-10-13
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 10 158 @ $0,55$6K · 2025-10-10
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 30 000 @ $0,47$14K · 2025-10-08
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,45$4K · 2025-10-07
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,45$4K · 2025-10-03
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 9 210 @ $0,45$4K · 2025-10-03
    • BP4 S.r.l.10% owner · Common Stock, Par Value $0.001Sold 10 000 @ $0,59$6K · 2025-09-11

    Short positioning

    166.2Kshares short-36.7% vs prior
    1.31days to cover
    44.4%short of daily vol
    1.5Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    MLSS.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): -20.3%Derived (calculated)
    • EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -16.7%Derived (calculated)
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 26.0%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): -51.8%Derived (calculated)
    • R&D expense (YoY) (2025-12-31 vs 2024-12-31): -47.7%Derived (calculated)
    • Operating income (YoY) (2025-12-31 vs 2024-12-31): 15.7%Derived (calculated)
    • Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): 0.1%Derived (calculated)
    • Return on equity (FY 2025-12-31): -203.4%Derived (calculated)
    • Return on assets (FY 2025-12-31): -73.3%Derived (calculated)
    • Current ratio (FY 2025-12-31): 1.81xDerived (calculated)
    • Debt-to-equity (FY 2025-12-31): 1.78xDerived (calculated)
    • EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -16.7%Derived (calculated)
    • Cost of revenue (YoY) (2025-12-31 vs 2024-12-31): 16.9%Derived (calculated)
    • Net income (YoY) (2025-12-31 vs 2024-12-31): -21.4%Derived (calculated)
    • Capex (YoY) (2025-12-31 vs 2024-12-31): 49.4%Derived (calculated)
    • Gross profit (YoY) (2025-12-31 vs 2024-12-31): -0.4%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -66.2%Derived (calculated)
    • Total liabilities (annual): USD 4.99MSEC XBRL filing
    • Total assets (annual): USD 7.81MSEC XBRL filing
    • Current liabilities (annual): USD 4.13MSEC XBRL filing
    • Current assets (annual): USD 7.48MSEC XBRL filing
    • Gross profit (annual): USD 6.41MSEC XBRL filing
    • EPS (basic) (annual): USD-PER-SHARES -0SEC XBRL filing
    • Operating income (annual): USD -5.7MSEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    2026-06-09FILING424B1 filing →
    2026-05-13FILING10-Q filing →
    2026-05-06FILING8-K filing →
    2026-05-06FILING8-K filing →
    2026-04-21FILING8-K filing →
    2026-04-02FILING8-K filing →
    2026-03-31FILING10-K filing →
    2026-03-11FILING8-K filing →
    2026-01-20FILING8-K filing →
    2025-12-23FILING8-K filing →
    2025-11-13FILING8-K filing →
    2025-11-13FILING10-Q filing →
    2025-10-24 00:00 UTCINSIDER12 insider transactions — 2025-10 · net sell $168k
    2025-10-24INSIDERBP4 S.r.l. sold 100.0k sh Common Stock, Par Value $0.001 — 10% owner ~$44k
    2025-10-23INSIDERBP4 S.r.l. sold 80.0k sh Common Stock, Par Value $0.001 — 10% owner ~$34k
    2025-10-22INSIDERBP4 S.r.l. sold 14.4k sh Common Stock, Par Value $0.001 — 10% owner ~$6k
    2025-10-21INSIDERBP4 S.r.l. sold 40.0k sh Common Stock, Par Value $0.001 — 10% owner ~$18k
    2025-10-20INSIDERBP4 S.r.l. sold 24.0k sh Common Stock, Par Value $0.001 — 10% owner ~$11k
    2025-10-14INSIDERBP4 S.r.l. sold 30.0k sh Common Stock, Par Value $0.001 — 10% owner ~$16k
    2025-10-13INSIDERBP4 S.r.l. sold 10.0k sh Common Stock, Par Value $0.001 — 10% owner ~$6k
    2025-10-10INSIDERBP4 S.r.l. sold 10.2k sh Common Stock, Par Value $0.001 — 10% owner ~$6k
    2025-10-08INSIDERBP4 S.r.l. sold 30.0k sh Common Stock, Par Value $0.001 — 10% owner ~$14k
    2025-10-07INSIDERBP4 S.r.l. sold 10.0k sh Common Stock, Par Value $0.001 — 10% owner ~$4k
    2025-10-03INSIDERBP4 S.r.l. sold 10.0k sh Common Stock, Par Value $0.001 — 10% owner ~$4k
    2025-10-03INSIDERBP4 S.r.l. sold 9.2k sh Common Stock, Par Value $0.001 — 10% owner ~$4k
    2025-09-11 00:00 UTCINSIDER1 insider transaction — 2025-09
    2025-09-11INSIDERBP4 S.r.l. sold 10.0k sh Common Stock, Par Value $0.001 — 10% owner ~$6k
    2025-07-17 00:00 UTCINSIDER4 insider transactions — 2025-07
    2025-06-30 00:00 UTCINSIDER15 insider transactions — 2025-06 · net sell $201k
    2025-05-30 00:00 UTCINSIDER3 insider transactions — 2025-05
    2024-12-19 00:00 UTCINSIDER1 insider transaction — 2024-12
    2024-10-22 00:00 UTCINSIDER1 insider transaction — 2024-10 · net sell $100k
    2024-09-24 00:00 UTCINSIDER3 insider transactions — 2024-09
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage